XML 107 R95.htm IDEA: XBRL DOCUMENT v3.25.1
Segment Reporting - Reconciliation of Adjusted EBITDA (Details) - USD ($)
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Segment Reporting Information [Line Items]    
Revenue [1] $ 483,649,000 $ 639,653,000
Depreciation and amortization expenses 24,058,000 29,503,000
Interest income (1,274,000) (2,550,000)
Interest expense 10,385,000 5,997,000
Gain (loss) from equity method investees 19,000.0 (306,000)
Provision from income taxes 1,470,000 565,000
Change in tax receivables agreement liability 0 173,000
Net loss attributable to common shareholders of Evolent Health, Inc. - basic (72,250,000) (25,225,000)
Net loss attributable to common shareholders of Evolent Health, Inc. - diluted (72,250,000) (25,225,000)
Total compensation expense by financial statement line item 11,081,000 18,786,000
Severance and termination benefits    
Segment Reporting Information [Line Items]    
Restructuring charges 1,000,000.0 400,000
Cost of revenue    
Segment Reporting Information [Line Items]    
Total compensation expense by financial statement line item 657,000 1,005,000
Selling, general and administrative expenses    
Segment Reporting Information [Line Items]    
Total compensation expense by financial statement line item 10,424,000 17,781,000
Acquisition related costs 700,000 0
Repositioning costs 0 9,900,000
Reportable segment    
Segment Reporting Information [Line Items]    
Revenue 483,649,000 639,653,000
Medical expense and device costs 292,676,000 431,336,000
Cost of revenue excluding medical expense and device costs and other segment items 87,845,000 103,206,000
Selling, general and administrative expenses excluding other segment items 66,268,000 51,014,000
Depreciation and amortization expenses 24,058,000 29,503,000
Interest income (1,274,000) (2,550,000)
Interest expense 10,385,000 5,997,000
Gain (loss) from equity method investees 19,000 (306,000)
Provision from income taxes 1,470,000 565,000
Change in tax receivables agreement liability 0 173,000
Other segment items $ 74,452,000 $ 45,940,000
[1] See Note 18 for amounts attributable to unconsolidated related parties included in these line items.